Check out your Company Bowl for anonymous work chats.
Precigen's UltraPorator™ Receives FDA Clearance for Manufacturing UltraCAR-T® Cells in Clinical Trials
Precigen’s collaborators at the University of Washington’s Institute of Translation Health Sciences Gene and Cell Therapy Lab are partnering to manufacture UltraCAR-T cells overnight to treat advanced ovarian cancer patients for the PRGN-3005 clinical trial.
Preclinical Data for PRGN-3005 UltraCAR-T® Demonstrate Superior Expansion and Persistence of UltraCAR-T Compared to Traditional CAR-T
Check out the interview in CEO-CFO Magazine with our CEO Dr. Helen Sabzevari on Precigen's therapeutic platform.
Precigen, Inc. today announced preclinical data for its innovative investigational PRGN-3005 UltraCAR-T™ in patients with advanced, recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer will be presented as an e-poster at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, to be held from June 22-24, 2020. The e-poster presentation titled PRGN-3005 UltraCAR-T: Multigenic CAR-T Cells Generated Using Non-viral Gene Delivery and Rapid Manufacturing Process for the Treatment of Ovarian Cancer (Abstract 6593) is part of the Immunology/Adoptive Cell Therapy session and will be accessible on the AACR e-poster website on June 22, 2020.
Check out our NEW Precigen website! A great resource for information on Precigen and our subsidiaries.
Precigen Announces Clearance of IND to Initiate Phase I/II Study for First-in-Class PRGN-2009 AdenoVerse™ Immunotherapy to Treat HPV-positive (HPV+) Solid Tumors
Precigen Completes Series Of Transactions To Solidify Healthcare Focus
Precigen Receives FDA Orphan Drug Designation
intrexon announced today that it will refocus the company on healthcare, change its name to Precigen, Inc. and, effective immediately, has appointed Helen Sabzevari, PhD, as President and CEO.
